Instrument NameUltragenyx PharmaceuInstrument Symbol(RARE-Q)

Instrument ExchangeNASDAQ

Analysts Are Bullish on These Healthcare Stocks: Ultragenyx Pharmaceutical (RARE), Vir Biotechnology (VIR)

Ultragenyx Gains FDA Priority Review for DTX401 Therapy

Ultragenyx to Participate at Investor Conferences in March

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NASDAQ: RARE: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.

Wedbush Reaffirms Their Hold Rating on Ultragenyx Pharmaceutical (RARE)

Analysts Offer Insights on Healthcare Companies: Baxter International (BAX) and Ultragenyx Pharmaceutical (RARE)

TD Cowen Remains a Buy on Ultragenyx Pharmaceutical (RARE)

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE), American Well (AMWL) and BridgeBio Pharma (BBIO)

Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Ultragenyx Pharmaceutical (RARE)

Ultragenyx Launches Restructuring Plan to Cut Costs

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Pfizer (PFE)

Ultragenyx Highlights New UX111 Data in FDA Resubmission

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains...